Sentence examples for trail combination from inspiring English sources

The combination indexes for LBH589 (e.g., 12.5 nM) and TRAIL (3.125 26 ng/ml) combination in the tested cell lines were <0.5 (Fig. 1C), indicating that LBH589 and TRAIL combination exerts synergistic effects on decreasing cell survival of pancreatic cancer cells.

As demonstrated above, the combination of LBH589 and TRAIL effectively decreased cell survival in Lac Z- or survivin-expressing cell lines, but failed to do so in both cell lines that express ectopic FLIPL (Fig. 4B), indicating the enforced expression of ectopic FLIPL, rather than survivin, confers cell resistance to augmented induction of apoptosis by LBH589 and TRAIL combination.

To confirm the results in vitro, we treated primary AML (N=8) and blast crisis chronic myeloid leukemia (BC-CML, N=7) primary cells with the Med and TRAIL combination for 48 h.

As the synergistic induction of cell death by TRAIL and doxorubicin was also observed in untransformed primary human hepatocytes, our results also point out potentially deleterious effects of TRAIL combination therapy in promoting undesired liver destruction.

Knockdown of Bid had also suppressed apoptosis by TRAIL or TRAIL combinations in colon carcinoma and mesothelioma cells.

The massif east of Bergen offers a great many trail combinations, of which the five-hour Vidden hike back to Fløyen is probably the most famous.

LC50 values for mitoxantrone-TRAIL and mithramycin-TRAIL combination treatments were 0.6 and 0.2 μM, respectively, for PC3-TR cells.

The average difference between analysis methods is 10.4% for mithramycin alone and only 5.6% for the mithramycin-TRAIL combination treatment.

In comparison, the LC50 values for the mitoxantrone-TRAIL combination treatments were 0.66 μM for BXPC-3 and 0.1 μM for MIAPaCa2 cells.

While the results with mitoxantrone are promising due to the observed selectivity, an effective chemotherapeutic window of operation may be available for the mithramycin-TRAIL combination in vivo.

The LC50 values for the mithramycin-TRAIL combination treatments were less than 0.1 μM (100 nM) for both, BXPC-3 and MIAPaCa2 cells.